Compare SAM & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SAM | CELC |
|---|---|---|
| Founded | 1984 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Medical Specialities |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 3.1B |
| IPO Year | 1996 | 2017 |
| Metric | SAM | CELC |
|---|---|---|
| Price | $233.13 | $115.05 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 8 |
| Target Price | ★ $229.50 | $100.13 |
| AVG Volume (30 Days) | 146.7K | ★ 528.5K |
| Earning Date | 06-01-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 95.45 | N/A |
| EPS | ★ 9.89 | N/A |
| Revenue | ★ $1,964,994,000.00 | N/A |
| Revenue This Year | $1.22 | N/A |
| Revenue Next Year | $1.46 | N/A |
| P/E Ratio | $23.38 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $186.72 | $7.58 |
| 52 Week High | $260.00 | $120.32 |
| Indicator | SAM | CELC |
|---|---|---|
| Relative Strength Index (RSI) | 54.72 | 62.68 |
| Support Level | $210.53 | $97.75 |
| Resistance Level | $252.10 | $120.32 |
| Average True Range (ATR) | 10.25 | 5.25 |
| MACD | -0.88 | 0.85 |
| Stochastic Oscillator | 60.20 | 87.20 |
Boston Beer is a top player in high-end malt beverages and adjacent categories in the US, with strong positions in craft beer, flavored malt beverages, hard cider, and hard seltzer. The bulk of volume and revenue is concentrated in four brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly. Beverages are produced using a hybrid model leveraging both in-house capacities and third-party breweries through contract arrangements. While the firm is required to use distributors to reach end markets, including retailers and on-premises operators, it also employs 500 internal sales representatives to educate the market about its products. The firm generates almost all sales in the US.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.